Neuphoria Therapeutics (NEUP) Share-based Compensation (2022 - 2026)

Neuphoria Therapeutics (NEUP) has reported Share-based Compensation for 5 consecutive years, with $300000.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 489.92% year-over-year to $300000.0 in Q1 2026; TTM through Mar 2026 was $300000.0, a 489.92% increase from a year earlier, with the FY2025 full-year figure at $200000.0, down 75.45% from the prior year.
• Share-based Compensation was $300000.0 for Q1 2026 at Neuphoria Therapeutics, up from $136770.0 in the prior quarter.
• Over five years, Share-based Compensation peaked at $97.4 million in Q3 2024 and troughed at $40031.0 in Q1 2024.
• A 5-year average of $18.0 million and a median of $137027.0 in 2025 frame the typical range for Share-based Compensation.
• The widest YoY moves for Share-based Compensation: up 69273.95% in 2024, down 99.86% in 2024.
• Over 5 years, Share-based Compensation stood at $56.6 million in 2022, then tumbled by 98.68% to $746936.0 in 2023, then plunged by 93.19% to $50854.0 in 2024, then soared by 168.95% to $136770.0 in 2025, then soared by 119.35% to $300000.0 in 2026.
• The last three Share-based Compensation figures came in at $300000.0 (Q1 2026), $136770.0 (Q4 2025), and $137027.0 (Q3 2025), per Business Quant data.